Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jul 23:16:1532878.
doi: 10.3389/fphar.2025.1532878. eCollection 2025.

The role of ubiquitination and deubiquitination in urological tumours

Affiliations
Review

The role of ubiquitination and deubiquitination in urological tumours

Lifeng Gan et al. Front Pharmacol. .

Abstract

The ubiquitin (Ub) system has been demonstrated to play a crucial role in various cellular processes, including immune responses, cell development, and programmed cell death. Ubiquitination, a form of post-translational modification, occurs in eukaryotic cells and involves several key components, such as Ub-activating enzymes, Ub-binding enzymes, and Ub-protein ligases. Recently, deubiquitinating enzymes-proteases that reverse the modification of proteins by removing Ub or Ub-like molecules, or by remodeling Ub chains on target proteins-have been identified as significant regulators of ubiquitination-mediated degradation. These enzymes profoundly influence cellular pathways and numerous biological processes, including the DNA damage response and DNA repair mechanisms. Recent studies increasingly demonstrate a relationship between ubiquitination, deubiquitination, and urinary diseases. The roles of these processes in urinary diseases are complex, encompassing various aspects of signaling, protein stability, and cellular metabolism. As research advances, the specific mechanisms by which these processes influence urologic diseases will be further clarified. This review examines recent discoveries in this field, aiming to provide new strategies and targets for the diagnosis and treatment of urologic diseases.

Keywords: deubiquitination; molecular mechanisms; targeted therapy; ubiquitination; urinary system.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Molecular mechanisms by which ubiquitination and deubiquitination regulate substrate degradation: in the ubiquitination phase (left), ubiquitin-activating enzyme (E1) consumes ATP, attaches ubiquitin (Ub) to itself via a thioester bond, and subsequently transfers it to ubiquitin-conjugating enzyme (E2), where ubiquitin conjugating enzyme (E3) covalently binds the ubiquitin to substrate proteins to form a multimeric ubiquitin chain (Ub+) that labels the substrate and is degraded by the proteasome (Degraded substrate). In the deubiquitination phase (right), deubiquitinating enzymes (Dub) shear the ubiquitin chain, reversing the ubiquitination process and maintaining substrate protein stability. PPi, pyrophosphoric acid; Ub, ubiquitin; Dub, deubiquitination.
FIGURE 2
FIGURE 2
Compounds target ubiquitination in urological disorders. AHR, Aromatic hydrocarbon receptor; MDM2, Mouse double minute 2; VHL, Von Hippel Lindau; TRIM, The tripartite motif; LPP, Lipoma preferred partner.

Similar articles

References

    1. Antao A. M., Tyagi A., Kim K. S., Ramakrishna S. (2020). Advances in deubiquitinating enzyme inhibition and applications in cancer therapeutics. Cancers (Basel) 12, 1579. 10.3390/cancers12061579 - DOI - PMC - PubMed
    1. Balakirev M. Y., Tcherniuk S. O., Jaquinod M., Chroboczek J. (2003). Otubains: a new family of cysteine proteases in the ubiquitin pathway. EMBO Rep. 4, 517–522. 10.1038/sj.embor.embor824 - DOI - PMC - PubMed
    1. Benjamin D. I., Cozzo A., Ji X., Roberts L. S., Louie S. M., Mulvihill M. M., et al. (2013). Ether lipid generating enzyme AGPS alters the balance of structural and signaling lipids to fuel cancer pathogenicity. Proc. Natl. Acad. Sci. U. S. A. 110, 14912–14917. 10.1073/pnas.1310894110 - DOI - PMC - PubMed
    1. Berndsen C. E., Wolberger C. (2014). New insights into ubiquitin E3 ligase mechanism. Nat. Struct. Mol. Biol. 21, 301–307. 10.1038/nsmb.2780 - DOI - PubMed
    1. Bhat K. P., Ümit Kaniskan H., Jin J., Gozani O. (2021). Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease. Nat. Rev. Drug Discov. 20, 265–286. 10.1038/s41573-020-00108-x - DOI - PMC - PubMed

LinkOut - more resources